tigger transposable element derived 4Genealiases: []
Q-omics provides the consensus-scored TIGD4 profile across patient tissues and cancer cell-line models. TIGD4 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, TIGD4 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, TIGD4 RNA expression shows 19,579 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCEC, KICH, and THYM as cancer lineages where TIGD4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TIGD4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TIGD4 survival associations across molecular data types. TIGD4 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TIGD4 RNA expression–survival associations across cancer types. High TIGD4 expression shows unfavorable associations in CESC, LGG and LIHC, but favorable associations in UCEC, KIRC and READ. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for TIGD4 RNA expression.
This table summarizes TIGD4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in KICH for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TIGD4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TIGD4 shows lower tumor expression in KICH, KIRC and LUSC and higher tumor expression in COAD, LIHC and STAD. The KICH box plot shows higher TIGD4 RNA expression in normal versus tumor tissue (log2 FC = −1.060, t-test p < 0.001).
This table shows molecular features associated with TIGD4 in patient tissues and cancer cell lines. In patient samples, TIGD4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TIGD4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
